Drug targets defective protein that causes cystic fibrosis
November 18th, 2010 - 4:43 pm ICT by ANILondon, Nov 18 (ANI): A new small study has shown that an investigational drug targeting a defective protein that causes cystic fibrosis (CF) can improve lung function.
The investigational drug, VX-770, appeared to improve function of what is known as CFTR–the faulty protein responsible for CF and is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis.
Patients who took VX-770 for 28 days showed improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels.
“Patients with CF have a defective protein in chloride channels in lung cells that, in effect, causes a door to shut too tightly, ultimately leading to severe infections in the lung” said Steven M. Rowe, assistant professor of medicine at the University of Alabama at Birmingham and lead investigator at the UAB site.
“The data suggest that the drug seems to improve the function of the protein, so that the door opens and closes more properly,” he added.
Investigators studied 39 patients with CF in the trial who had a specific mutation in the gene known to cause CF with the primary objective of demonstrating the safety and tolerability of VX-770. All patients in the trial completed use of the study drug, and adverse events were similar to placebo.
VX-770 is currently in Phase 3 clinical trials for cystic fibrosis, and, pending data from these studies, Vertex anticipates submitting a new drug application to the FDA in the second half of 2011.
CF is a fatal genetic disease that affects 70,000 people worldwide. It is caused by a genetic mutation that causes life-threatening lung infections and premature death.
Findings are published in the New England Journal of Medicine. (ANI)
- Scientists one step closer to a drug treatment for cystic fibrosis - Oct 13, 2010
- Protein involved in cystic fibrosis linked to chronic lung diseases - Dec 30, 2010
- Novel drug may benefit cystic fibrosis patients - Dec 18, 2010
- Crosstalk between ion channels leads to new therapeutic strategy - Sep 20, 2010
- New drug raises hope for cystic fibrosis patients - Sep 10, 2008
- Infliximab treatment effective for cystic fibrosis and Crohn's disease - Apr 20, 2010
- Growth defects in patients with cystic fibrosis 'may start before birth' - Nov 10, 2010
- Vitamin D may prevent or treat allergy to common mould - Aug 17, 2010
- Experimental drug shows promise for cystic fibrosis treatment - Aug 21, 2008
- New bacterial foe in cystic fibrosis identified - Oct 02, 2010
- Boffins come closer to understanding how cystic fibrosis causes lung disease - Apr 29, 2010
- Vitamin D may treat allergy to common mold - Aug 26, 2010
- Common cold virus may help treat cystic fibrosis - Jul 21, 2009
- Inhalation therapy proves effective against cystic fibrosis - Feb 06, 2009
- Model shows promise to develop therapies for protein folding diseases - Apr 28, 2011
Tags: cause of cystic fibrosis, chloride channels, chloride levels, cystic fibrosis, cystic fibrosis patients, drug targets, england journal of medicine, fatal genetic disease, faulty protein, genetic mutation, investigational drug, journal of medicine, lung cells, lung function, lung infections, new england journal, new england journal of medicine, potential difference, sweat chloride, university of alabama at birmingham